Literature DB >> 10462249

Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy.

I J Caley1, M R Betts, N L Davis, R Swanstrom, J A Frelinger, R E Johnston.   

Abstract

A live virus vaccine vector has been constructed from a molecularly cloned attenuated strain of Venezuelan equine encephalitis virus (VEE). High levels of foreign protein expression are regulated by an additional copy of the 26 S viral subgenomic RNA promoter. The position of this additional promoter and foreign gene in the VEE genome was predicted to have a major influence on expression level of the heterologous protein. Two sites in the genome were tested to determine the optimal site for expression of the matrix/capsid (MA/CA) coding region of human immunodeficiency virus (HIV-1). One vector contained the additional promoter and the MA/CA genes immediately downstream of the VEE E1 gene at the 3' end of the genome. In the second vector, the additional promoter was introduced immediately upstream from the authentic 26 S subgenomic promoter. Significantly higher levels of MA/CA were expressed from the downstream vector compared to the upstream vector. However, the stability of expression for both vectors was similar following passage in baby hamster kidney cells (BHK) cells. In BALB/c mice, the two vectors elicited similar levels of cellular immune responses to MA/CA as determined by bulk cytotoxic T-lymphocyte assays and precursor frequency analysis, but the humoral response induced by the downstream vector was significantly stronger. At 11 months post boosting with the downstream vector, serum antibody levels against HIV MA/CA were undiminished, and MA/CA specific CTLp were detectable in all mice tested. These findings suggest that VEE vectors can be optimized to elicit strong, balanced and long-lived immune responses to foreign viral proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462249     DOI: 10.1016/s0264-410x(99)00142-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  A novel self-replicating chimeric lentivirus-like particle.

Authors:  Christy K Jurgens; Kelly R Young; Victoria J Madden; Philip R Johnson; Robert E Johnston
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.

Authors:  Patrick R Harrington; Boyd Yount; Robert E Johnston; Nancy Davis; Christine Moe; Ralph S Baric
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.

Authors:  Xuemin Chen; Michael T Rock; Jason Hammonds; James Tartaglia; Ayumi Shintani; Jeff Currier; Bonnie Slike; James E Crowe; Mary Marovich; Paul Spearman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles.

Authors:  U B Balasuriya; H W Heidner; J F Hedges; J C Williams; N L Davis; R E Johnston; N J MacLachlan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression.

Authors:  Shreya Kanodia; Diane M Da Silva; Tigran Karamanukyan; Lies Bogaert; Yang-Xin Fu; W Martin Kast
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

Review 7.  Vaccine development against HIV-1: current perspectives and future directions.

Authors:  Rebecca L Edgeworth; Juan Homero San; Jason A Rosenzweig; Nang L Nguyen; Jean D Boyer; Kenneth E Ugen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

8.  Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization.

Authors:  Jin-Won Youn; Su-Hyung Park; Jae Ho Cho; Young Chul Sung
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32.

Authors:  Kevin P Nishimoto; Amanda K Laust; Edward L Nelson
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

10.  Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.

Authors:  Shinya Abe; Kenji Okuda; Takehiro Ura; Asami Kondo; Atsushi Yoshida; Shinji Yoshizaki; Hiroyuki Mizuguchi; Dennis Klinman; Masaru Shimada
Journal:  J Gene Med       Date:  2009-07       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.